Cite
HARVARD Citation
Bergin, K. et al. (2021). A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial. British journal of haematology. pp. 580-586. [Online].